Cellular soldiers created using the body’s own defenses can track down and kill cancer cells that escape during surgeries, researchers report.
This could prevent metastasis and save lives, particularly in cases of triple-negative breast cancer.
Researchers attached two proteins to the surface of lipid nanoparticles: TNF-related apoptosis-inducing ligand—or TRAIL—and the adhesion receptor E-selectin. The injected nanoparticles then adhere to white blood cells, and the introduction of these TRAIL-coated leukocytes into the bloodstream before, during, and after tumor removal kills all cancer cells loosed as a result.
“Collisions between the TRAIL-coated leukocytes and cancer cells in the bloodstream are happening constantly,” says Michael King, a professor of engineering and chair of the biomedical engineering department at Vanderbilt University.
“We’ve tested this both in the bloodstream and in hundreds of blood samples from cancer patients being treated in clinics across the country. In all cases, within two hours, the viable cancer cells are cleared out. This has worked with breast, prostate, ovarian, colorectal, and lung cancer cells.”
Not only can the method work during surgeries, King says, but also potentially with patients who already suffer metastatic cancer in multiple sites and who have no worthwhile treatment options. Because all the components of the TRAIL-coated leukocytes occur naturally in the body, it increases the potential for a quicker path from the bloodstreams of mouse models to human trials.
Surgical intervention in breast cancer is a known cause of metastatic growth and accelerated tumor relapse, either because of cancer cells shed during the process, inflammation at the wound site, or a combination of the two factors. Chemotherapy is the most widely used treatment for the resulting metastasis, but still, the five-year survival rate for triple negative breast cancer sits well below 30%.
The group’s past experiments with TRAIL-coated leukocytes were effective in blocking metastasis, but required multiple repeated injections to sustain their beneficial effect. King says this new breakthrough overcomes those issues by designing three simple doses to coincide with the surgical procedure.
The paper appears in Science Advances. Support for the work came from the National Institute of Health and the NCI/NIH Cancer Center.
Source: Vanderbilt University